Explore All 959 Buyout (LBO, MBO, MBI) Software Deals - Search the Database Free
M&A Deal Summary |
|
|---|---|
| Date | January 1, 2022 |
| Target | Qinecsa Solutions |
| Sector | Software |
| Buyer(s) | Stanley Capital |
| Deal Type | Buyout (LBO, MBO, MBI) |
FILTER BY
Stanley Capital is a private equity partnership that pursues healthcare and technology investments. The Firm targets businesses valued from $250 million to $2.5 billion with defensible business models and opportunities for growth. Stanley Capital was formed in 2019 and is headquartered in London.
| Deal Context for Buyer | # |
|---|---|
| Overall | 2 of 4 |
| Sector: Software | 1 of 1 |
| Type: Buyout (LBO, MBO, MBI) | 1 of 1 |
| Country: United Kingdom | 1 of 1 |
| Year: 2022 | 1 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-09-09 |
Noden Pharma DAC
Dublin, Ireland Noden Pharma DAC is a global specialty pharmaceutical company that is focused on acquiring prescription medicines across a range of therapeutic areas. Noden Pharma DAC holds exclusive worldwide rights to manufacture, market, and sell Tekturna® and Tekturna HCT (or Rasilez and Rasilez HTC outside of the United States), which contain aliskiren, a direct renin inhibitor, for the treatment of hypertension. In March 2019, Noden announced the U.S commercial launch of an authorized generic form of Tekturna, aliskiren hemifumarate 150 mg, and 300 mg tablets with the same drug formulation as Tekturna. Noden Pharma DAC is headquartered in Dublin, Ireland. |
Buy | $53M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-10-04 |
Laboratoire X.O
Saint-Cloud, France Laboratoire X.O is a pharmaceutical company offering drugs, medical devices, and cosmetic products. Laboratoire X.O was founded in 2015 and is based in Saint-Cloud, France. |
Buy | - |
